MedTrace Logo

Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve

NCT03438500 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-10-31

No results posted yet for this study

Summary

The purpose of the study is to assess the feasibility of Cardiac Shock Wave Treatment in patients with anginal chest pain and evidence of abnormal myocardial perfusion under stress in the absence of significant stenoses of the epicardial coronary arteries.

Conditions

Interventions

DEVICE

Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)

40 - 60 spots per visit (200 shots/spot) at Energy Level 3

Sponsors & Collaborators

  • Technical University of Munich

    collaborator OTHER

  • Storz Medical AG

    lead INDUSTRY

Principal Investigators

  • Georg Schmidt, Prof. Dr. · Technische Universität München I. Medizinische Klinik und Poliklinik

  • Alexander Steger, Dr. med. · Technische Universität München I. Medizinische Klinik und Poliklinik

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2022-09-01
Completion
2022-09-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03438500 on ClinicalTrials.gov